Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of the Dose of Erythropoiesis Stimulating Agents on Cardiac-cerebrovascular Outcomes Quality of Life and Costs in Hemodialysis Patients. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial
Brief Summary: Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option.

The purpose of this study is

1. the evaluation of biochemical markers to determine the efficacy of individual prediction of ESAs therapy
2. to determine the benefits and harms of different ESA doses therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD).


Options:
A: Arm Label: Cohort A (0.4/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort B (0.4/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort C (0.4/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort D (0.8/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort E (0.8/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort F (0.8/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort G (1.2/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort H (1.2/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort I (1.2/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort A (0.4/150, 1x/ Week), Cohort B (0.4/150, 1x/ 3 Weeks), Cohort C (0.4/150, 1x/ 4 Weeks), Cohort D (0.8/150, 1x/ Week), Cohort E (0.8/150, 1x/ 3 Weeks), Cohort F (0.8/150, 1x/ 4 Weeks), Cohort G (1.2/150, 1x/ Week), Cohort H (1.2/150, 1x/ 3 Weeks), Cohort I (1.2/150, 1x/ 4 Weeks)
B: Arm Label: CinnaPoietin®; Type: EXPERIMENTAL; Interventions: Drug: CinnaPoietin®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Arm Label: Eprex®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eprex®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Intervention Type: DRUG; Name: CinnaPoietin®; Assigned to Arm(s): CinnaPoietin® | Intervention Type: DRUG; Name: Eprex®; Assigned to Arm(s): Eprex® | Intervention Type: DRUG; Name: Nephrovit; Assigned to Arm(s): CinnaPoietin®, Eprex® | Intervention Type: DRUG; Name: Vitamin B12 Injection; Assigned to Arm(s): CinnaPoietin®, Eprex®
C: Arm Label: Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: QM; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Q2W, QM
D: Arm Label: ESAs 1 low dose; Type: EXPERIMENTAL; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Arm Label: ESAs 2 high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 1 low dose | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 2 high dose

Answer: D